Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

Simon Fraser University

$33,000.00

Characterization of stem cell-derived human dopaminergic neuron subtypes

EF 2022-23

Résumé
Canada is a leader in research on movement disorders, especially Parkinson's Disease (PD). As the second most common neurodegenerative condition, PD is responsible for substantial economic, societal, and personal burden. Efforts to uncover effective approaches to treat PD patients are a high priority, and research to help us better understand how neurons are lost in the brains of PD patients is essential to reach therapeutic goals. Dopaminergic (DA) neurons have long been known as the cell type affected in PD; recent findings have revealed that this cell population is more complex than we previously thought and there are actually more than six subtypes of DA neurons. Some of these subtypes are more susceptible than others in PD. This is an important discovery with clinical implications, but our current understanding of DA neuron subtypes is limited.Incredibly, neuroscience researchers are now able to generate human DA neurons in the lab from easy to generate stem cells derived from human patients, termed induced pluripotent stem cells (iPSCs). iPSC-derived DA neurons have served as powerful tools to model the onset and progression of PD, and to uncover potential therapeutic compounds in large-scale screening experiments. There are substantial limitations, however, to our current protocols for iPSC-DA neuron generation. These include inefficient differentiation (typically, only ~30% of neurons generated are of DA identity) and a lack of knowledge as to which DA neuron subtypes are produced. In this proposal we will use high throughput compound screening and imaging methods to improve the efficiency of iPSC-derived DA neuron production and permit reliable stratification of the subgroups produced. Our goal is to optimize existing protocols so researchers can directly produce individual subgroups of DA neurons from iPSCs. This proposal will harness the complementary expertise of: 1) the Julian and Vocadlo labs at Simon Fraser University, experts in neuroscience, biological regulation of cell fate determination and high-throughput analysis; and 2) Dr. Erin Knock and her Neuroscience team at STEMCELL Technologies, an internationally renowned Vancouver-based company with long established expertise in optimization of iPSC neuronal differentiation strategies. Our team is uniquely poised to conduct this work that we anticipate will substantially impact the PD and movement disorder research communities.
Programme
Alliance Grants
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
571911-2022
Name nom
Julian, Lisa LM
Department département
Biological Sciences
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
33000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
5105
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell differentiation
Research subject fr
Différenciation cellulaire
Installment
inst:1
Partie
1
Nb partie
1
Application title
Characterization of stem cell-derived human dopaminergic neuron subtypes
Application summary
Canada is a leader in research on movement disorders, especially Parkinson's Disease (PD). As the second most common neurodegenerative condition, PD is responsible for substantial economic, societal, and personal burden. Efforts to uncover effective approaches to treat PD patients are a high priority, and research to help us better understand how neurons are lost in the brains of PD patients is essential to reach therapeutic goals. Dopaminergic (DA) neurons have long been known as the cell type affected in PD; recent findings have revealed that this cell population is more complex than we previously thought and there are actually more than six subtypes of DA neurons. Some of these subtypes are more susceptible than others in PD. This is an important discovery with clinical implications, but our current understanding of DA neuron subtypes is limited.Incredibly, neuroscience researchers are now able to generate human DA neurons in the lab from easy to generate stem cells derived from human patients, termed induced pluripotent stem cells (iPSCs). iPSC-derived DA neurons have served as powerful tools to model the onset and progression of PD, and to uncover potential therapeutic compounds in large-scale screening experiments. There are substantial limitations, however, to our current protocols for iPSC-DA neuron generation. These include inefficient differentiation (typically, only ~30% of neurons generated are of DA identity) and a lack of knowledge as to which DA neuron subtypes are produced. In this proposal we will use high throughput compound screening and imaging methods to improve the efficiency of iPSC-derived DA neuron production and permit reliable stratification of the subgroups produced. Our goal is to optimize existing protocols so researchers can directly produce individual subgroups of DA neurons from iPSCs. This proposal will harness the complementary expertise of: 1) the Julian and Vocadlo labs at Simon Fraser University, experts in neuroscience, biological regulation of cell fate determination and high-throughput analysis; and 2) Dr. Erin Knock and her Neuroscience team at STEMCELL Technologies, an internationally renowned Vancouver-based company with long established expertise in optimization of iPSC neuronal differentiation strategies. Our team is uniquely poised to conduct this work that we anticipate will substantially impact the PD and movement disorder research communities.